MedTrace Logo

Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11

NCT00015301 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2017-02-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate PET methodology to study in vivo synaptic dopamine release.

Conditions

  • Cocaine-Related Disorders
  • Substance-Related Disorders

Interventions

DRUG

Methylphenidate

Sponsors & Collaborators

  • New York MDRU

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • John Rotrosen, M.D. · New York MDRU

Study Design

Purpose
DIAGNOSTIC
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2005-06-30
Completion
2005-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00015301 on ClinicalTrials.gov